My take away's from the podcast:
When refering to COVID-19 trials "in these 12 patients Using the exact same protocol as we are using for GvHD" - will allow them to apply for a label extension prior to obtaining full approval
"If the results are positive we can seek approval from the FDA for patients with acute respiratory distress syndrome" - this requires them to obtain sufficient data points, which will require sufficient patient enrollment and secondary objectives will come into play
Re-emphasises it will take 3-4 months for total patient recruitment - we're nearly 3 months in
Shorter-term focus:
- GvHD
- COVID-ARDs, then other forms of ARDs (influenza and bacterial mediated etc)
- Other acute inflammatory conditions that are life threatening, including other forms of acute inflammatory lung disease
Longer term focus:
- Cardiac-related
- Pain-related
I anticipate we won't get any positive news until next month. GLTA
- Forums
- ASX - By Stock
- MSB
- MSB - Most exciting 6 months
MSB - Most exciting 6 months, page-378
-
- There are more pages in this discussion • 352 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.11 |
Change
0.010(0.91%) |
Mkt cap ! $1.261B |
Open | High | Low | Value | Volume |
$1.09 | $1.11 | $1.07 | $4.794M | 4.399M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 14500 | $1.10 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.11 | 141676 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 14500 | 1.100 |
2 | 93112 | 1.095 |
2 | 37684 | 1.090 |
3 | 40400 | 1.085 |
2 | 61100 | 1.080 |
Price($) | Vol. | No. |
---|---|---|
1.110 | 141676 | 5 |
1.115 | 41050 | 3 |
1.120 | 157964 | 9 |
1.125 | 61233 | 3 |
1.130 | 111595 | 5 |
Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |